Suppr超能文献

胸段硬膜外镇痛用于肝移植术后疼痛管理:一项对685例肝移植受者的10年研究。

Thoracic Epidural Analgesia for Postoperative Pain Management in Liver Transplantation: A 10-year Study on 685 Liver Transplant Recipients.

作者信息

Hausken John, Haugaa Håkon, Hagness Morten, Line Pål-Dag, Melum Espen, Tønnessen Tor Inge

机构信息

Department of Anesthesiology, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.

Department of MEVU, Lovisenberg University College, Oslo, Norway.

出版信息

Transplant Direct. 2021 Jan 7;7(2):e648. doi: 10.1097/TXD.0000000000001101. eCollection 2021 Feb.

Abstract

BACKGROUND

Thoracic epidural analgesia (TEA) is not widely used for postoperative pain management in liver transplantation due to hepatic coagulopathy-related increased risk of inducing an epidural hematoma. However, an increasing number of patients are transplanted for other indications than the end-stage liver disease and without coagulopathy allowing insertion of an epidural catheter.

METHODS

This study is a retrospective observational single-center study of all adult patients undergoing first-time liver transplantation at Oslo University Hospital between January 1, 2008, and December 31, 2017. Data regarding patient characteristics were obtained from the Nordic liver transplant registry, medical records, and pain registration forms. Patients without coagulopathy (international normalized ratio <1.5 and platelets >100 × 10/L) were eligible for TEA.

RESULTS

Out of 685 first-time liver transplantations in a 10-year period, 327 received TEA, and 358 did not. The median Model of End-stage Liver Disease score was lower in the TEA group than in the non-TEA-group (9 versus 17, < 0.001), and fewer patients were hospitalized preoperatively (16 versus 127, < 0.001). The median international normalized ratio (1.1 versus 1.6, < 0.001) and platelet count (190 versus 78, < 0.001) were different between the TEA and non-TEA groups. There were no serious complications related to insertion or removal of the TEA catheters. Patients in the TEA group had less pain with a mean numeric rating scale at postoperative days 0-5 of 1.4 versus 1.8 ( = 0.008). Nearly 50% of the patients were prescribed opioids when discharged from hospital (non-TEA 154 versus TEA 158, = 0.23), and there was no difference after 1 year ( = 0.718).

CONCLUSIONS

Our report revealed very good pain control with both TEA and the non-TEA modality. TEA was without any serious complications like epidural hematoma or infection/abscess in selected liver transplant recipients without severe coagulopathy. Opioid prescription at hospital discharge and by 1-year follow-up did not differ between the groups.

摘要

背景

由于肝凝血功能障碍导致硬膜外血肿风险增加,胸段硬膜外镇痛(TEA)在肝移植术后疼痛管理中未得到广泛应用。然而,越来越多的患者因终末期肝病以外的其他适应症接受移植,且没有凝血功能障碍,从而可以插入硬膜外导管。

方法

本研究是一项回顾性观察性单中心研究,纳入了2008年1月1日至2017年12月31日期间在奥斯陆大学医院接受首次肝移植的所有成年患者。有关患者特征的数据来自北欧肝移植登记处、病历和疼痛登记表。无凝血功能障碍(国际标准化比值<1.5且血小板>100×10⁹/L)的患者符合TEA条件。

结果

在10年期间的685例首次肝移植中,327例接受了TEA,358例未接受。TEA组的终末期肝病模型评分中位数低于非TEA组(9对17,P<0.001),术前住院的患者较少(16对127,P<0.001)。TEA组和非TEA组之间的国际标准化比值中位数(1.1对1.6,P<0.001)和血小板计数(190对78,P<0.001)不同。与TEA导管插入或拔除相关的严重并发症未出现。TEA组患者疼痛较轻,术后0-5天的平均数字评分量表评分为1.4,而非TEA组为1.8(P=0.008)。近50%的患者出院时开具了阿片类药物(非TEA组154例对TEA组158例,P=0.23),1年后无差异(P=0.718)。

结论

我们的报告显示TEA和非TEA方式均能很好地控制疼痛。在选定的无严重凝血功能障碍的肝移植受者中,TEA没有硬膜外血肿或感染/脓肿等严重并发症。两组在出院时和1年随访时的阿片类药物处方无差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d44/7793348/8110acac2d0e/txd-7-e648-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验